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Bordetella pertussis and Bordetella bronchiseptica establish respiratory infections with notorious efficiency. Our previous stud-
ies showed that the fhaB genes of B. pertussis and B. bronchiseptica, which encode filamentous hemagglutinin (FHA), are func-
tionally interchangeable and provided evidence that FHA-deficient B. bronchiseptica induces more inflammation in the lungs of
mice than wild-type B. bronchiseptica. We show here that the robust inflammatory response to FHA-deficient B. bronchiseptica
is characterized by the early and sustained influx of interleukin-17 (IL-17)-positive neutrophils and macrophages and, at 72 h
postinoculation, IL-17-positive CD4 T cells, suggesting that FHA allows the bacteria to suppress the development of an IL-17-
mediated inflammatory response. We also show that the cyaA genes of B. pertussis and B. bronchiseptica, which encode adenyl-
ate cyclase toxin (ACT), are functionally interchangeable and that ACT, specifically its catalytic activity, is required for B. bron-
chiseptica to resist phagocytic clearance but is neither required for nor inhibitory of the induction of inflammation if bacteria are
present in numbers sufficient to persist during the first 3 days postinoculation. Incubation of bone marrow-derived macro-
phages with a cyaA strain caused decreased production of IL-1 and increased production of tumor necrosis factor alpha
(TNF-) and IL-12, while incubation with a cyaA fhaB strain caused increased production of IL-23. These data suggest that
FHA and ACT both contribute to suppress the recruitment of neutrophils and the development of an IL-17-mediated immune
response. To our knowledge, this is the first demonstration of a microbial pathogen suppressing IL-17-mediated inflammation
in vivo as a strategy to evade innate immunity.
Bordetella bronchiseptica is a Gram-negative bacterium that in-fects a broad range of mammalian species, typically colonizing
the nasopharynx and trachea of its hosts chronically and asymp-
tomatically (9, 10, 19, 26). Bordetella pertussis, which diverged
from a B. bronchiseptica-like ancestor approximately 3 million
years ago, infects only humans and causes whooping cough (or
pertussis), an acute respiratory disease that is especially severe in
young children and infants (72). Both of these organisms are ca-
pable of establishing respiratory infections in a highly efficient
manner (48), suggesting that they possess specific strategies for
resisting or overcoming innate immune clearance mechanisms
operative in the respiratory tract. Molecular mechanisms under-
lying these strategies are not well understood.
Despite differences in host range and disease-causing propen-
sity, B. pertussis and B. bronchiseptica produce a similar set of vir-
ulence factors that include filamentous hemagglutinin (FHABp
and FHABb, respectively) and adenylate cyclase toxin (ACT) (55).
ACT is a member of the RTX (repeat in toxin) family of bacterial
pore-forming toxins. It is a unique fusion of a cytolysin with an
N-terminal adenylate cyclase (AC) enzyme (67). ACT is first syn-
thesized as a protein called CyaA (encoded by the cyaA gene) and
then acylated by the product of the cyaC gene to become the active
toxin. ACT can bind to the 2 integrin of Mac-1 (CD11b/CD18)
expressed on myeloid cells, such as macrophages, neutrophils,
dendritic cells, and natural killer cells (7, 21, 28, 29). Upon entry
into the cell, ACT is activated by binding to eukaryotic calmodulin
(71) and catalyzes unregulated conversion of ATP to cyclic AMP
(cAMP). By elevating cAMP levels, ACT dysregulates cellular sig-
naling pathways and suppresses superoxide production (oxidative
burst), chemotaxis, and phagocytosis in macrophages and neutro-
phils (8, 15). ACT-deficient B. pertussis and B. bronchiseptica are
cleared from the lungs of mice faster than wild-type bacteria (11,
32), presumably because they are unable to inhibit the bactericidal
activities of phagocytic cells. Recent studies, however, suggest that
ACT may also contribute to infection by affecting secretion of
cytokines and chemokines in epithelial cells and macrophages.
For example, purified ACT can inhibit production of interleu-
kin-12 (IL-12) and tumor necrosis factor alpha (TNF-) and aug-
ment production of IL-6 and IL-10 in lipopolysaccharide (LPS)-
activated human monocyte-derived dendritic cells (MDDC) and
macrophages (5, 13, 33, 60, 67), suggesting that ACT functions as a
down-regulator of inflammation. Perkins et al., however, showed
that purified ACT synergizes with LPS to induce cyclooxygenase 2
(COX-2) in epithelial cells and murine macrophages, suggesting
that ACT may potentiate the inflammatory response to B. pertussis
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infection (57). Consistent with a proinflammatory role, Dunne et
al. recently reported that ACT promotes robust IL-1 production
by dendritic cells via activation of the NALP3 inflammasome
complex and consequently polarizes the T cell response toward
the Th17 subtype (20), which would cause enhanced neutrophil
infiltration and activity (41).
FHA, encoded by the fhaB gene, is a large, rod-shaped, immu-
nogenic protein that is both surface associated and secreted into
the extracellular milieu (39, 51). FHA is a prototypic member of
the two partner secretion (TPS) pathway. It is synthesized as an
370-kDa preproprotein (FhaB) with a 71-amino-acid (aa) sig-
nal sequence and a C-terminal 130-kDa prodomain that is re-
moved at some point during translocation across the outer mem-
brane, resulting in the mature 240-kDa FHA protein (50). FHA
is required for colonization of the lower respiratory tract by B.
bronchiseptica and mediates bacterial attachment to a variety of
cell lines in vitro (17, 38, 43, 64, 66, 69). Recent studies using a
mouse model suggest that FHA plays an important role in modu-
lating the host innate immune response early during infection (36,
40). In vitro studies with B. pertussis or FHA purified from B.
pertussis have also suggested an immunomodulatory role for FHA.
For example, prolonged exposure of U-937 macrophages and hu-
man monocytes to FHA resulted in the cytosolic accumulation of
IB and the inability of TNF- to activate NF-B (1), and Mills
and colleagues showed that purified FHA could mitigate IL-12
secretion by a macrophage cell line, ex vivo alveolar macrophages,
and bone marrow-derived dendritic cells and could induce a sub-
set of IL-10-secreting regulatory T cells in vitro (52, 53).
Several studies have suggested that ACT function may depend,
at least in part, on FHA. Weiss and Falkow demonstrated that
more ACT is released from FHA-deficient B. pertussis strains than
from wild-type B. pertussis (68). Zaretzky et al. showed that ACT
can interact with FHA and that the presence of ACT on the bac-
terial surface correlates with the presence of FHA (74). It was also
demonstrated that the bacteria-associated form of ACT generated
greater levels of cAMP than toxin isolated from the medium of
FHA mutant strains (74), and the presence of ACT in the outer
membrane has been proposed to play a role in the adherence func-
tion of FHA (56). These data have led to the hypothesis that FHA
acts as a delivery mechanism for ACT, increasing local concentra-
tions for more robust intoxication of target cells (74). Subsequent
work revealed that although a direct physical interaction between
FHA and ACT was not required, toxin delivery was enhanced by
close association of the bacteria with target cells (27).
The goal of this study was to investigate the contribution of
FHA and ACT to the early inflammatory response to Bordetella
infection. A majority of the studies investigating the involvement
of these virulence factors in influencing the host response have
been conducted using B. pertussis and/or purified B. pertussis pro-
teins in in vitro assays. B. bronchiseptica’s broad host range, how-
ever, allows the roles of various Bordetella virulence factors to be
studied in vivo in the context of a natural bacteria-host interaction
using laboratory animals such as rats and mice. We demonstrated
previously that FHA from B. pertussis (FHABp) can substitute for
FHA from B. bronchiseptica (FHABb) in vitro and in vivo (40). In
this study, we set out to determine if the ACT proteins of B. per-
tussis and B. bronchiseptica are also functionally interchangeable
and if ACT and FHA cooperate to control chemokine and cyto-
kine production in the lower respiratory tract as a strategy to fa-
cilitate persistence.
MATERIALS AND METHODS
Ethics statement. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory Ani-
mals of the National Institutes of Health. Our protocol was approved by
the University of North Carolina (UNC) IACUC (09-326 and 10-134) and
the University of California, Santa Barbara (UCSB), IACUC (6-04-601).
All animals were properly anesthetized for inoculations, monitored regu-
larly, and euthanized when moribund, and efforts were made to minimize
suffering.
Growth media and bacterial strains. Wild-type B. bronchiseptica
RB50 and mutant derivatives were grown at 37°C on Bordet-Gengou
(BG) agar (Becton, Dickinson Microbiology Systems) supplemented with
7.5% defibrinated sheep blood (Colorado Serum Co., Denver, CO) or in
Stainer-Scholte (SS) broth supplemented with 100 mg/ml (2,6-O-dimethyl)-
-cyclodextrin (63). Escherichia coli strains were cultured in LB agar or broth.
Where appropriate, medium was supplemented with gentamicin (Gm; 30
g/ml), streptomycin (Sm; 20 g/ml), diaminopimelic acid (DAP; 20 g/
ml), or sucrose (8.3%). For E. coli, 100 g/ml ampicillin (Ap) was used for
plasmid selection.
All strains and relevant plasmids used in this study are listed in Table
S1 in the supplemental material. Strains containing unmarked, in-frame
chromosomal deletions or mutations in the cyaA and fhaB genes were
constructed using allelic exchange methods described previously (2, 37).
All strains are derivatives of B. bronchiseptica strain RB50, a wild-type
isolate recovered from the nares of a naturally infected 3-month-old New
Zealand White rabbit (16). The cyaA strain, RB515, was generated using
allelic exchange plasmid pCI56, which contains an in-frame deletion of
codons 5 to 1701 of B. bronchiseptica cyaA (cyaABb). The fhaB strain,
RBX9, was described previously (17). Strain RB509 produces a catalyti-
cally inactive form of CyaA and was generated using plasmid pCI54,
which contains two mutations (encoding H63A and K65A substitutions)
in the AC domain-encoding region of cyaABb. To create a B. bronchiseptica
strain expressing cyaA from B. pertussis, the entire cyaA gene and pro-
moter from B. pertussis Tohama I was cloned into a pBR322 derivative
(pEG7) that can be used as a suicide vector in Bordetella. The resulting
plasmid, designated pDB05, was introduced into RB515, the B. bron-
chiseptica strain containing a deletion of the cyaA gene. Strain RBX1128
produces an FhaB protein containing which contains a 28-aa deletion
near the C terminus of mature FHA as described previously (40). All
strains were confirmed to be constructed as intended by PCR and DNA
sequence analysis.
Immunoblotting. To evaluate production of ACT and FHA, proteins
were prepared from B. bronchiseptica cultures grown overnight in SS
broth to stationary phase. For whole-cell lysates, protein was extracted
from a 1-ml culture by boiling in phosphate-buffered saline (PBS)–2
sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
sample buffer with dithiothreitol (DTT). Proteins present in filtered cul-
ture supernatants were precipitated with trichloroacetic acid and resus-
pended in 10 mM Tris (pH 8.0)–2 SDS-PAGE sample buffer with DTT.
Proteins were separated using SDS-PAGE (5% polyacrylamide), trans-
ferred to nitrocellulose, and probed with a mouse monoclonal antibody
that was generated against CyaA (3D1; Santa Cruz Biotechnology) and a
rabbit polyclonal antibody that was generated against a polypeptide
corresponding to the mature C-terminal domain (MCD) of B. bron-
chiseptica FHA (40). Goat anti-mouse secondary antibody conjugated
to IRdye 680 and goat anti-rabbit secondary antibody conjugated to
IRdye 800 (Molecular Probes) were used to detect antigen-antibody
complexes. The anti-CyaA antibody was used at a dilution of 1:5,000,
the anti-FHA antibody was used at a dilution of 1:1,000, the anti-
mouse secondary antibody was used at a dilution of 1:15,000, and the
anti-rabbit secondary antibody was diluted 1:25,000. Antigen-anti-
body complexes were visualized using an Odyssey infrared imaging
system (LiCor Biosciences).
Culture of J774A.1 cells. J774A.1 cells (murine macrophage cell line)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with
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high glucose (Gibco) plus 10% heat-inactivated fetal bovine serum
(Gibco) in 5% CO2 at 37°C.
Intoxication of J774 cells. J774 cells were grown overnight in 96-well
tissue culture plates at 40,000 cells/well. Bacterial strains were grown over-
night in liquid broth (SS), diluted to an optical density at 650 nm (OD650)
of 0.1, and grown to logarithmic phase. Cultures were centrifuged and
separated into supernatant and pellet fractions, and the bacterial pellets
were resuspended to their original volume in medium. An equal volume
(equivalent to 107 to 108 bacteria) of each fraction was added to the J774
cells and incubated for 30 min at 37°C. Cells were washed three times with
Hank’s balanced salt solution (HBSS) and lysed for 30 min at room tem-
perature, and intracellular cAMP was measured with a Tropix chemilu-
minescent enzyme-linked immunosorbent assay (ELISA) system (Ap-
plied Biosystems). Intoxication is reported as a function of total J774 cell
protein.
Intranasal inoculation and cytokine and histological analysis. (i)
Mouse experiments performed at UCSB. Three- to four-week-old
BALB/c mice (Charles River Laboratories, Wilmington, MA) were inoc-
ulated intranasally with 5  105 CFU of B. bronchiseptica in 50 l of PBS.
The lungs were harvested at 3 h, 3 days, and 11 days postinoculation (p.i.)
(see Fig. 4B), and the numbers of CFU from right lungs were determined
by plating lung tissue homogenates on BG agar as described previously.
These experiments were performed as described in the animal use proto-
cols that have been approved by the UCSB IACUC (6-04-601).
(ii) Mouse experiments performed at UNC. Four-week-old BALB/c
mice from Jackson Laboratories (Bar Harbor, ME) were inoculated intra-
nasally with 1  105 or 5.5  105 CFU of B. bronchiseptica in 50 l of PBS
(see Fig. 1, 2, 3, and 5). Mice were infected with strains RB50, RBX9,
RB515, RB516, and RBX1128 (or PBS as a negative control). Where
indicated in the figure legends, mice were inoculated with high doses (106
or 107 CFU) of strain RB516 (see Fig. 6). Lungs were harvested from
infected mice at 3 h, 12 h, 24 h, 48 h, 72 h, or 11 days p.i. Right lungs were
homogenized in 1 ml of PBS containing a protease inhibitor cocktail
(Roche). Serial dilutions of homogenized lung tissue were plated on BG
agar to assess bacterial burden. At the times indicated on the figures, the
cytokine response to infection was evaluated using a Milliplex bead-based
immunoassay (Millipore) run on a Luminex detector. Undiluted right
lung homogenates were centrifuged at 3,800  g for 10 min, and the
supernatants were passed through a 0.22-m-pore-size filter. Filtrates
were analyzed as per the manufacturer’s instructions for using serum/
plasma. Cytokines/chemokines of interest were selected from mouse
panel I (Millipore) and included the following: TNF-, IL-1, IL-6, IL-17,
keratinocyte-derived chemokine (KC), macrophage inflammatory pro-
tein 1 (MIP-1), MIP-2, IL-12p70, and monocyte chemotactic protein 1
(MCP-1). Cytokine concentrations were calculated using standard curve
data for each analyte (range of detection was 3.2 to 25,000 pg/ml). To
evaluate gross pulmonary inflammation, left lung lobes harvested from
mice at 72 h p.i. were inflated with 10% formalin, embedded in paraffin,
sectioned at 5 m, stained with hematoxylin and eosin (H&E), and ex-
amined by microscopy. Immunohistochemistry was performed by fol-
lowing instructions for deparaffinization and epitope recovery according
to Abcam specifications. Antibody for primary binding to Ly6G was pur-
chased from Abcam, and Alexa Fluor 568-conjugated secondary antibody
(Invitrogen) was used for detection on an Olympus FV1000. Animals that
became moribund were immediately euthanized. The data shown in Fig.
2A and 5A are from two independent experiments, with all strains being
used in both experiments. The data are shown in separate figures for
clarification of the response to mutant strains. The results of the wild-type
strain, however, are shown in both figures for reference. These experi-
ments were performed as described in the animal use protocols that have
been approved by the UNC IACUC (protocols. 09-326 and 10-134).
Lung digestion and intracellular cytokine staining. Animals were
deeply (sublethal) anesthetized via intraperitoneal injection of 340 mg/kg
Avertin and subsequently euthanized by severing the renal artery and
performing a thoracotomy. Lungs were transcardially perfused with PBS.
The trachea was ligated using silk suture, and lungs were infused with 1 ml
of dispase II (Roche, Indianapolis, IN) via tracheal injection and allowed
to incubate. Lungs were excised, and tissue was macerated in PBS-DNase
(Sigma-Aldrich) and passed through a 70-m-pore-size strainer. Cells
were stimulated for 1 h with phorbol myristate acetate (PMA)-ionomycin
(Sigma), then incubated with brefeldin A (Sigma) for 5 h in RPMI me-
dium (Gibco). Hybridoma 2.4G2 supernatant was added to block Fc re-
ceptors for 1 h, and then Pacific orange succinimidyl ester (Invitrogen)
was used at a concentration for discerning live and dead cells. Cells were
next surface stained for CD11b, CD11c, F4/80, Ly6G/C, CD8, CD4, CD3,
CD49b, CD45, and 	 T cell receptor (TCR) (BD Pharmingen, eBiosci-
ence). Cells were permeabilized, fixed, and then stained with anti-IL-17A,
according to the manufacturer’s instructions (BD Pharmingen). Analysis
was performed on a Beckman Coulter CyAn Flow cytometer (Brea, CA)
using Summit, version 4.3, software (Beckman Coulter).
Bone marrow-derived macrophages. Bone marrow-derived macro-
phages were prepared by culturing cells harvested from the femur and
tibia of C57BL/6 mice in DMEM (Sigma) supplemented with 10% fetal
bovine serum (FBS; PAA). L929 cell supernatants (DMEM) were used as
a source of growth factors and were added to the medium at 25% of the
total volume. Macrophages were cultured for 7 days, with fresh medium
being added every 3 days; adherent cells were infected, harvested, and
analyzed by flow cytometry to verify purity prior to immunoassay.
In vitro cytokine immunoassay. Bone marrow-derived macrophages
were seeded at 1  106 cells/ml into a 24-well tissue culture treated dish
(BD Biosciences) on day 6 of culture and allowed to adhere overnight.
Prior to bacterial infection, medium was harvested, and 200 l of fresh
medium was added. B. bronchiseptica strains were added at a multiplicity
of infection (MOI) of 10 in 100 l of PBS and were cultured for 2 h.
Bacterial supernatants were then aspirated, and cells were washed once
with PBS, followed by the addition of 1 ml of fresh medium supplemented
with 30 g/ml gentamicin sulfate (Fisher Scientific). Supernatants were
harvested and analyzed via ELISA for TNF-, IL-1, IL-12p70, IL-6, IL-10
(BD Biosciences), IL-23(p19/p40), and TGF-1 (R&D Systems) accord-
ing to the manufacturer’s instructions. The lowest level of detection was
calibrated to 15.1 pg/ml. Absorbance was determined using a Molecular
Devices plate reader and analyzed by Softmax Pro software (Molecular
Devices). After removal of supernatants for the ELISA, the macrophages
were washed twice with PBS containing 2.5% FBS and then incubated
with antibodies for CD11b, CD80, CD86, F4/80, CD11c (eBioscience),
and major histocompatibility complex (MHC) class II I-A (BD Phar-
mingen) for 1 h. Cells were washed twice and analyzed on a CyAN using
Summit, version 4.3, software (Dako). Live cells were gated via forward
and side scatter profiles, and single-cell events were determined via pulse
width. Purity was determined to be 93 to 97%.
Statistical analyses. Statistical analyses were performed using Prism,
version 5.0, software from GraphPad Software, Inc. Statistical significance
was determined using an unpaired student’s t test or analysis of variance
(ANOVA).
RESULTS
FHA-deficient B. bronchiseptica induces a more robust inflam-
matory response than wild-type B. bronchiseptica, independent
of dose and bacterial burden. We showed previously that inocu-
lation of BALB/c mice with 5  105 CFU of FHA-deficient B.
bronchiseptica cells results in a “bimodal” response: half of the
animals appear moribund by day 3 p.i. and have very high num-
bers of bacteria in their lungs (108 CFU) and massive influx of
inflammatory cells in their lung tissues, and half of the animals
appear healthy, contain 3  105 CFU in their lungs on day 3 p.i.,
and have only low levels of inflammatory cells in their lung tissues
(36, 40). Animals that are healthy at day 3 p.i. clear the FHA-
deficient bacteria from their lungs by day 11 p.i. We hypothesized
that our standard dose, 5  105 CFU, is the 50% lethal dose (LD50)
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for FHA-deficient B. bronchiseptica and that a robust inflamma-
tory response is generated in all animals inoculated with this
strain. We reasoned that this robust inflammatory response either
clears the infection quickly (animals that remain healthy) or
causes tissue damage that allows for increased bacterial growth,
more inflammation, and more tissue damage, ultimately resulting
in the death of the mouse. To test this hypothesis, we inoculated
mice with a slightly lower dose (1  105 CFU) or a slightly higher
dose (5.5  105 CFU) and determined bacterial burden in the
lungs and lung pathology at days 0, 1, 3, and 11 p.i. The slightly
higher dose was determined empirically. We discovered that in-
creasing the dose from 5.0  105 CFU to 5.5  105 CFU was
sufficient to eliminate the bimodal response. Repeating the exper-
iment twice more with more animals produced the same results, as
shown here. All mice inoculated with the higher dose of the fhaB
strain (RBX9) had nearly 2 logs more CFU in their lungs than mice
inoculated with wild-type B. bronchiseptica (RB50) at 72 h p.i. and
were moribund (hence, all of these animals were euthanized, and
so there are no data for this group at day 11 p.i.); in contrast, all
mice inoculated with the lower dose of RBX9 remained overtly
healthy and had substantially fewer CFU in their lungs at 72 h p.i.,
and many cleared the bacteria from their lungs by day 11 p.i. (Fig.
1A). None of the mice inoculated with wild-type bacteria showed
signs of illness or respiratory distress at any time p.i. For these
animals, bacterial numbers in the lungs increased during the first
72 h p.i. and then decreased to about 104 to 105 CFU by day 11 p.i.
(Fig. 1A). The left lungs of each animal were fixed, sectioned,
stained with H&E, and examined microscopically (Fig. 1B and C).
Sections from animals inoculated with 1  105 CFU (Fig. 1B) were
also stained with anti-Ly6G antibody followed by Alexa Fluor 568-
conjugated secondary antibody and examined by fluorescence mi-
croscopy to identify neutrophils. Sections from the lungs of ani-
mals inoculated with the lower dose of wild-type bacteria showed
only very mild inflammation. At 72 h p.i., the majority of cellular
infiltrate was localized in the alveolar interstitium, causing mild
atelectasis. Few fusions of alveolar septae were observed, and
perivascular inflammation was moderate. Small accumulations of
mononuclear leukocytes (most likely lymphocytes) were present
but no significant microscopic lesions. The proportion of cells that
stained positively with the anti-Ly6G antibody was small. Regard-
less of dose, the lungs of mice inoculated with the fhaB strain
showed substantially more inflammation, characterized by bron-
chial cuffing and increased infiltration of neutrophils (as shown by
staining with anti-Ly6G antibody), macrophages, and mononu-
clear leukocytes, than the lungs of mice inoculated with wild-type
bacteria (Fig. 1B and C). FHA-deficient B. bronchiseptica, there-
fore, induced a more robust inflammatory response than wild-
type bacteria, independent of bacterial burden, supporting the
hypothesis that FHA allows B. bronchiseptica to suppress the initial
inflammatory response to infection.
Increased production of proinflammatory cytokines, espe-
cially IL-17, in the lungs of animals infected with FHA-deficient
B. bronchiseptica. To characterize the initial inflammatory re-
FIG 1 Bacterial burden and lung pathology in mice inoculated with low and
high numbers of CFU of wild-type and fhaB B. bronchiseptica bacteria. (A)
Bacterial burden in mice at 3 h, 24 h, 72 h, and 11 days postinoculation fol-
lowing delivery of 50 l of PBS containing doses of 1  105 (low) or 5.5  105
(high) CFU of B. bronchiseptica strains as indicated. Each symbol represents an
individual animal. Horizontal black lines show the mean for each group. The
horizontal dashed line represents the lower limit of detection. Asterisks indi-
cate a statistically significant difference where compared (*, P 
 0.05; **, P 

0.001; ***, P 
 0.0001). The data are from two independent experiments. (B)
Inflammation of mouse lung tissue at 24 and 72 h p.i.; animals were infected
with 1  105 CFU. H&E-stained 5-m lung sections were examined by light
microscopy for peribronchiolar and perialveolar infiltrate and by assessing
hypertrophy of bronchiolar epithelial cells. Representative sections were
viewed at a magnification of 40. Neutrophil infiltration at 24 h p.i. from
animals infected with 1  105 CFU of wild-type or FHA-deficient bacteria at a
magnification of 60. Antibody against Ly6G and 4=,6=-diamidino-2-phe-
nylindole nuclear stain were used to identify cells. (C) H&E-stained sections
from animals infected with 5.5  105 CFU of wild-type (RB50) or fhaB
(RBX9) B. bronchiseptica bacteria at 24 and 72 h p.i. at a magnification of 40.
d, days; wt, wild type.
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sponse to wild-type and FHA-deficient B. bronchiseptica more
thoroughly, we inoculated BALB/c mice with 5.5  105 CFU and
evaluated bacterial burden and chemokine and cytokine levels in
lung homogenates at 3, 12, 24, 48, and 72 h p.i. As expected,
wild-type B. bronchiseptica increased in number by approximately
1 log during the first 72 h p.i. (Fig. 2A), and animals showed no
signs of respiratory distress throughout the course of the experi-
ment. We measured cytokine and chemokine levels in the lungs
using multiplex technology (Fig. 2B; see also Fig. S2 in the sup-
plemental material) Figure 2B shows cytokine levels per ml of
lung homogenate while Fig. S2 shows cytokine levels per ml of
homogenate per log10 CFU. Neither wild-type nor mutant B.
bronchiseptica induced significant IL-10, gamma interferon
(IFN-), or IL-12p70 production in these mice (data not
shown). Lung homogenates from mice inoculated with wild-
type bacteria contained appreciable levels of TNF- at 3 h p.i.
and lower levels at later time points. KC, MIP-2, and MIP-1
levels were increased at 72 h compared with levels in homoge-
nates from PBS-inoculated mice. Lung homogenates from
mice inoculated with wild-type bacteria also contained signif-
icantly increased levels of IL-1 and IL-6.
As expected, mice inoculated with 5.5  105 CFU of the
fhaB strain exhibited signs of respiratory distress and mild
weight loss at 72 h p.i. and had significantly greater numbers of
CFU in their lungs at 48 and 72 h p.i. than mice inoculated with
wild-type bacteria (Fig. 2A). Lung homogenates from these
mice had greater amounts of TNF- at 3 h p.i. than lung ho-
mogenates from mice inoculated with wild-type bacteria. The
chemokines MCP-1, KC, and, notably, IL-17 were significantly
higher in lung homogenates from mice infected with the fhaB
strain than in homogenates from mice infected with wild-type
bacteria at 72 h p.i. (Fig. 2B), suggesting a greater IL-17-medi-
ated response in mice infected with FHA-deficient B. bron-
chiseptica.
FIG 2 Impact of FHA on the early chemokine/cytokine response to infection. (A) Bacterial burden in mouse lungs at indicated times p.i., in hours. Each point represents
the number of CFU recovered from the right lung of a single animal. Horizontal black lines show the mean for each group. (B) Chemokine and cytokine production after
infection with wild-type strain RB50 (gray circles) and thefhaB strain RBX9 (red diamonds) or PBS (control; open diamonds with a center dot). Levels of TNF-, IL-1,
IL-6, IL-17, KC, MIP-1, MIP-2, IFN-, and MCP-1 (pg/ml) present in mouse lungs at 3, 12, 24, 48, and 72 h postinoculation of 5.5105 CFU of B. bronchiseptica strains
were measured with a Multiplex immunoassay. The lower limit of detection for all samples was 3.2 pg/ml. Significant differences between levels for animals infected with
wild-type bacteria and PBS-inoculated controls are indicated with daggers (†, P 
 0.05; ††, P 
 0.001; †††, P 
 0.0001), and significant differences between animals
infected with the fhaB strain and wild-type bacteria are indicated with asterisks (*, P 
 0.05; **, P 
 0.001; ***, P 
 0.0001).
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FHA-deficient B. bronchiseptica induces a sustained inflam-
matory response in the lungs, characterized by increased pro-
portions of IL-17-producing neutrophils, macrophages, and
CD4 T cells. To characterize the inflammatory response to wild-
type and fhaB bacteria at the cellular level, we inoculated addi-
tional groups of mice with 1  105 CFU. Two animals per group
were sacrificed at 3 h p.i. to determine the number of CFU deliv-
ered to the lungs (Fig. 3A). Of the animals sacrificed at 24, 48, and
72 h p.i., four per group were used to determine bacterial burden
and histopathology, and the results were consistent with previous
experiments (Fig. 3A and B). Lungs from the remaining three
animals per group were harvested and digested with dispase to
create a single suspension, and intracellular staining was per-
formed to identify cell types and the presence of IL-17. At 24 h p.i.
with wild-type B. bronchiseptica, the lungs contained a large pro-
portion of alveolar macrophages (20%), monocyte-derived
macrophages (30%), and neutrophils (20%) (Fig. 3C). Ap-
proximately 25% of the neutrophils and 4% of the monocyte-
derived macrophages stained positively for IL-17. Approximately
12% of the cells recovered at 24 h p.i. were CD4 T cells. Other
cells identified included dendritic cells, 	 T cells, NK cells, and
CD8 T cells. Although 	 T cells composed only 1% of the cells
recovered, 50% of them stained positively for IL-17. The cellular
profile at 48 h p.i. was similar to that at 24 h p.i., except that the
proportion of alveolar macrophages was greater and the propor-
tion of monocyte-derived macrophages was decreased. By 72 h
p.i., the cell types present in the lungs were consistent with recov-
ery from mild inflammation; the proportion of neutrophils was
less than 5%, the proportion of alveolar macrophages was about
20%, and the proportion of monocyte-derived macrophages was
about 40%, with approximately 15% of those cells staining posi-
tive for IL-17. A majority of the IL-17 detected in lung homoge-
nates at 72 h p.i. (Fig. 2B), therefore, appears to have been pro-
duced by activated macrophages.
Consistent with histological analyses (Fig. 3B), the lungs of
mice inoculated with the fhaB strain contained a significantly
greater proportion of neutrophils at 24 h p.i. than lungs of mice
inoculated with wild-type bacteria (Fig. 3C). Although the pro-
portion of monocyte-derived macrophages was less in mice inoc-
ulated with the fhaB strain than in mice inoculated with wild-
type bacteria, the proportion of those staining positive for IL-17
was much greater. At 48 h p.i., the proportion of neutrophils in the
lungs of mice infected with the fhaB strain dropped to about
14%, but a majority of those cells produced IL-17. At 72 h p.i., the
cellular profile in the lungs of mice inoculated with the fhaB
strain differed significantly from that of mice inoculated with
wild-type B. bronchiseptica; neutrophils composed a substantial
portion of the population with approximately 30% of those stain-
ing positively for IL-17, and the proportions of alveolar and
monocyte-derived macrophages were reversed. In addition, ap-
proximately 10% of the cells recovered were CD4 T cells, and
nearly all of those cells stained positively for IL-17. This cellular
profile indicates an ongoing neutrophil-mediated inflammatory
response with IL-17 apparently being produced by neutrophils,
activated macrophages, and CD4 T cells. These data indicate that
without FHA, B. bronchiseptica induces a robust and sustained
IL-17- and neutrophil-mediated inflammatory response that
leads to faster clearance of the bacteria from the lower respiratory
tract than infection by wild-type bacteria. FHA, therefore, allows
B. bronchiseptica to control the inflammatory response in a way
that allows the bacteria to persist in the lower respiratory tract for
extended periods of time.
FHA-dependent adherence in vitro does not correlate with
FHA-dependent function in vivo. B. bronchiseptica adheres to a
wide range of mammalian cell lines in vitro in an FHA-dependent
manner (40, 49). To explore the possibility that the hyperinflam-
matory response to infection by the fhaB strain is due to lack of
adherence-dependent delivery of immunomodulatory molecules
to host cells, we inoculated mice with a strain producing FHA with
a 28-aa deletion near the C terminus of the mature FHA protein
(called RBX1128) and compared the inflammatory response to
that induced by RB50 (wild type) and RBX9 (fhaB). RBX1128
adheres to epithelial cells and macrophage-like cell lines in vitro
similarly to wild-type B. bronchiseptica (40). The number of CFU
of RBX1128 recovered after inoculation with 1  105 CFU was
similar to that of wild-type B. bronchiseptica at 24 and 48 h p.i. and
was similar to that of the fhaB strain at 72 h p.i. (Fig. 3A). Exam-
ination of H&E-stained lung sections showed increased infiltra-
tion of inflammatory cells at 24 and 72 h p.i., similar to the lungs of
mice infected with the fhaB strain (Fig. 3B). Investigation of the
cell types present in the lungs at 24, 48, and 72 h p.i. indicated a
cellular infiltrate profile similar to that induced in response to
infection by the fhaB strain (Fig. 3C). In general, experiments
shown here as well as those published previously (40) indicate that
although RBX1128 is able to adhere to various cell lines in vitro,
similar to wild-type B. bronchiseptica, it is defective for lower re-
spiratory tract colonization and for suppressing inflammation in
the lungs, similar to fhaB B. bronchiseptica. These data suggest
that FHA itself may affect signaling in host cells to modulate the
inflammatory response, rather than functioning solely as an ad-
hesin, although we cannot rule out the possibility that RBX1128
is as defective as RBX9 at adhering to cells in vivo.
The cyaA gene from B. pertussis can substitute for the cyaA
gene of B. bronchiseptica. Our data suggest that FHA may be
playing a direct role in suppressing inflammation. If so, one or
more bacterial factors must be responsible for causing the robust
inflammation that occurs in response to infection by FHA-defi-
cient bacteria. Because ACT of B. pertussis has been proposed to
function in a proinflammatory manner based on in vitro studies
(57), we set out to test the hypothesis that ACT is proinflamma-
tory in vivo. We began by determining if the cyaA gene from B.
pertussis could substitute for the cyaA gene of B. bronchiseptica.
The predicted amino acid sequences of the ACT proteins pro-
duced by B. pertussis and B. bronchiseptica are 96% identical (55).
We cloned the cyaA gene from B. pertussis Tohama I on a suicide
plasmid and introduced this plasmid into a cyaA derivative
strain of B. bronchiseptica RB50 (see Materials and Methods and
Fig. S1A in the supplemental material). The resulting cyaA::
pcyaABp strain, designated RB515::pDB05, produced and secreted
ACT in a manner indistinguishable from that of wild-type RB50
(see Fig. S1B). The adenylate cyclase activity of cell-associated and
secreted protein was assayed by measuring the amount of intra-
cellular cAMP from infected macrophage-like cells, and the data
are displayed on a log scale (Fig. 4A). Activity values for the cyaA
strain were three orders of magnitude lower than for the wild-type
strain, essentially at the background level for the assay. The
cyaA::pcyaABp strain caused production of equivalent levels of
cAMP compared to the wild-type strain. To determine if cyaABp
can substitute for cyaABb during infection, we inoculated BALB/c
mice using our standard protocol (i.e., intranasal inoculation with
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FIG 3 Cellular environment and IL-17 production. (A) Bacterial burden in mouse lungs through 3 days of infection. Animals were infected with 1  105 CFU
of the B. bronchiseptica strain as indicated, and burden was assessed via multiple dilutions and enumeration of bacteria. 28, strain RBX1128. (B) Histological
sections (H&E stained) taken from the left lungs at 72 h p.i. at a magnification of 40. (C) Graphs represent percentages of identified cell types; inner,
lighter-shaded bars represent the portions of those cells staining positive for IL-17. Leukocyte subsets were identified as follows, with indicated levels of
expression: neutrophils, CD11b mid and Ly6G/C high; alveolar macrophages, CD11b mid-low, CD11c mid-low, and F4/80 low; monocytes/macrophages,
CD11b high, F4/80 mid-high, and CD11c negative; gamma delta (	) T cells, 	 TCR positive; CD4 T cells, CD3 and CD4 positive; CD8 T cells, CD3 and CD8
positive; dendritic cells, CD11b low-negative, CD11c high, and CD 8 positive/negative. All cells were first gated as being of appropriate forward and side scatter
dimensions, CD45 positive, and negative for the succinimidyl ester stain. Percentages are based on 500,000 events gated in the forward and side scatter gates.
Unidentified cells are those that expressed any of the markers used for detection other than CD45 or CD45 marker alone. Statistics are calculated as significant
variation from wild type (*, P 
 0.05; **, P 
 0.001; ***, P 
 0.0001).
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5  105 CFU). Consistent with previous data (32), fewer CFU of
the cyaA strain were recovered from the lungs at all time points
p.i. after 3 h (Fig. 4B). These results confirm a role for ACT in
resisting innate immune clearance. The number of CFU of the
cyaA::pcyaABp strain was similar to that of wild-type bacteria at
all time points, demonstrating that the B. pertussis cyaA gene can
substitute for the B. bronchiseptica cyaA gene in this murine
model. These data suggest that the ACT proteins of B. pertussis and
B. bronchiseptica are functionally interchangeable and that infor-
mation gleaned about the function of ACT using B. bronchiseptica
and natural host animal models may apply to B. pertussis ACT as
well. Because pcyaABp essentially complements the cyaA muta-
tion, these data also show that the phenotype displayed by the
cyaA strain is due only to the lack of cyaA and not polar effects or
other unintended mutations.
The catalytic activity of ACT is required for bacterial growth
in the lungs. To determine if the adenylate cyclase catalytic activ-
ity of ACT is required for ACT function in vivo, we used site-
directed mutagenesis and allelic exchange to construct a B. bron-
chiseptica strain producing ACT in which the histidine at position
63 and the lysine at position 65 were replaced with alanine residues
(67). The resulting strain, called RB509, which harbors a catalyti-
cally inactive cyaA gene, produced ACT protein in a manner in-
distinguishable from wild-type bacteria (see Fig. S1A in the sup-
plemental material) but lacked measurable adenylate cyclase activity
(Fig. 4A). The strain harboring the catalytically inactive cyaA gene was
recovered in numbers similar to the cyaA strain at days 3 and 11 p.i.
(Fig. 4B), demonstrating that the adenylate cyclase activity of ACT is
required for bacterial persistence in the lungs.
ACT is required to induce a sustained inflammatory re-
sponse, even under hyperinflammatory conditions induced by
FHA-deficient bacteria. We inoculated mice with 5.5  105 CFU
of wild-type bacteria, the cyaA strain, and a fhaB cyaA double
mutant and evaluated bacterial burden, lung pathology, and
chemokine and cytokine levels in lung homogenates at 3, 12, 24,
48, and 72 h p.i. As expected, the number of CFU of the cyaA
strain decreased over the course of the experiment (Fig. 5A). Mice
inoculated with the fhaB cyaA strain (RB516) had greater
numbers of CFU in their lungs at 12 and 24 h p.i. than mice
inoculated with the cyaA strain (Fig. 5), similar to the way that
mice infected with the fhaB strain at the low dose had greater
numbers of CFU at these time points than mice infected with
wild-type bacteria at the same dose (Fig. 1 and data not shown).
Whatever mechanism allows the fhaB mutants to grow to higher
numbers in the lungs than wild-type bacteria during the first 24 h
p.i., therefore, also appears to be operative for bacteria that do not
produce ACT. From 24 to 72 h p.i., the animals infected with the
fhaB cyaA strain showed a decrease of 2 log CFU compared to
those infected with the wild-type strain, suggesting that even
though the initial growth rate/survival capacity was increased sim-
ilar to the fhaB strain, the lack of ACT rendered the bacteria
incapable of persisting. Examination of H&E-stained lung sec-
tions of mice infected with the cyaA strain revealed very mild
multifocal alveolar hemorrhages (Fig. 5B). At 72 h p.i., perivascu-
lar accumulations of mononuclear leukocytes, composed mostly
of lymphocytes with some macrophages, and few neutrophils
were present. Histological analysis, as well as significantly lower
cytokine production during the course of infection (Fig. 5C), sug-
gests that a robust inflammatory response was not engendered,
and the lack of ACT shaped this response. Animals that had been
inoculated with the fhaB cyaA strain exhibited moderate in-
flammation at 12 h, primarily consisting of a large neutrophil
infiltrate (data not shown). At 24 and 48 h p.i., histological exam-
ination revealed fusions of alveolar septae, marked by fibrotic pro-
cesses, but these lesions were scattered diffusely rather than en-
compassing the entire lung as in the fhaB mutant (data not
shown). However, at 72 h p.i., lungs from mice infected with the
fhaB cyaA double mutant exhibited mild multifocal pneumo-
nia (Fig. 5B), with most of the lesions resolving, and nonsuppu-
rative perivasculitis predominating the tissue. Cytokine analysis of
the lungs from mice inoculated with fhaB cyaA B. bronchisep-
tica showed that bacteria elicited a modest inflammatory response
compared to animals inoculated with the wild-type strain (Fig.
5C; see also Fig. S2 in the supplemental material), yet TNF- levels
were increased at 12 h p.i., and MIP-1 levels were increased from
3 to 48 h p.i. These data suggest that a substantial inflammatory
response was generated in animals inoculated with the fhaB
cyaA strain, yet the response was limited due to the fact that the
bacterial burden was decreasing over time.
ACT is not absolutely required for induction of robust in-
flammation in response to FHA-deficient B. bronchiseptica. We
FIG 4 Functional interchangeability of ACT. (A) Toxin activity of ACT was
measured by the production of cAMP. Bars represent pmol of cAMP per mg of
protein of J774.1 macrophages, with solid bars representing supernatant-in-
cubated cells and striped bars representing cells incubated with resuspended
bacterial pellets. Asterisks indicate a statistically significant difference from
wild-type bacteria and the complemented strain RB515::pDB505 (*, P 
 0.05;
**, P 
 0.001; ***, P 
 0.0001). icyaA, catalytically inactive cyaA gene. (B)
BALB/c mice were inoculated intranasally with 50 l of PBS containing 5 
105 CFU of B. bronchiseptica strains as indicated, and the numbers of CFU in
the right lungs were determined at 3 h, 72 h, and 11 days p.i. Each point
represents the log CFU recovered from a single animal. Horizontal black lines
show the mean for each group. Asterisks indicate a statistically significant
difference from wild-type bacteria (*, P 
 0.05; **, P 
 0.001; ***, P 
 0.0001).
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hypothesized that lack of substantial induction of IL-6, KC, IL-17,
MIP-2, and MCP-1 in response to inoculation with the cyaA and
fhaB cyaA strains (Fig. 5) might be due to the relatively rapid
clearance of these strains rather than reflecting an activity of ACT.
We therefore inoculated mice with 5.5  105, 1  106, or 1  107
CFU of the cyaA fhaB (RB516) strain or 5.5  105 CFU of the
fhaB (RBX9) strain and measured bacterial burden and cytokine
and chemokine levels at various times p.i. As expected, animals
FIG 5 Impact of ACT on the early chemokine/cytokine response to infection. (A) Bacterial burden in mouse lungs at labeled times p.i., in hours. Each point
represents the number of CFU recovered from the right lung of a single animal. Horizontal black lines show the mean for each group. (B) Histological sections
(H&E stained) taken from the left lungs at 72 h p.i. at magnifications of 2 (inset) and 40. Photographs are representative samples of each population. (C)
Chemokine and cytokine production after infection with wild-type strain RB50 and the cyaA strain RB515, fhaB cyaA strain RB516, or PBS (control). Levels
of TNF-, IL-1, IL-6, IL-17, KC, MIP-1, MIP-2, and MCP-1 (pg/ml) present in mouse lungs at 3, 12, 24, 48, and 72 h postinoculation of 5.5  105 CFU of B.
bronchiseptica strains were measured with a Multiplex immunoassay. The lower limit of detection for all samples was 3.2 pg/ml. Statistics are calculated as
significant variation from wild type and where black bars indicate (*, P 
 0.05; **, P 
 0.001; ***, P 
 0.0001).
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inoculated with the fhaB strain at this dose were ill at 48 h p.i. and
moribund by 72 h p.i. Bacterial load at these times increased 2 and
3 logs, respectively, from the initial CFU numbers (Fig. 6A). When
administered at the lowest dose, the number of CFU of the fhaB
cyaA strain recovered was 1.5 logs less at 12 h and 72 h p.i. than
the level at 3 h p.i. Inoculation with the intermediate dose, 1  106
CFU, resulted in a bimodal response: half of the animals appeared
healthy, and the number of CFU recovered decreased at 48 and 72
h compared with the number recovered at 3 h p.i.; in contrast, the
other half showed evidence of acute disease, and the number of
CFU recovered increased at 48 and 72 h p.i. Inoculation of 107
CFU of the fhaB cyaA strain caused respiratory distress within
24 h and mild weight loss (4 to 7%) (data not shown) by 48 h, and
animals were moribund by 72 h p.i. The number of CFU in the
lungs increased to 8.8  108 by 72 h after infection (Fig. 6A).
Cytokine and chemokine levels in the lungs of mice inoculated
with 5.5  105 CFU of the fhaB cyaA strain were low or unde-
tectable at all time points, presumably because the bacterial num-
bers were too low to induce an appreciable response (Fig. 6B).
TNF-, MIP-1, and MIP-2 levels were statistically higher in mice
inoculated with 1  107 of the cyaA fhaB strain than in the mice
inoculated with the fhaB mutant. Although bacterial loads were
higher in the double mutant-inoculated mice than in RBX9-inoc-
ulated mice at 3 and 48 h p.i., they were similar at 72 h p.i., sug-
gesting that, at least at the 72-h time point, the increased cytokine
levels were not simply due to increased bacterial numbers. Levels
of IL-1, MCP-1, and IL-17 were not significantly different be-
tween mice inoculated with 1  107 CFU of RB516 and mice
inoculated with RBX9 at any time point, suggesting that ACT does
not play a role in controlling the production of these cytokines at
this dose. IL-6 and KC levels were dramatically higher in mice
inoculated with 1  107 CFU of the cyaA fhaB strain, beginning
with the earliest time point, than those of the lowest dose. These
responses may simply reflect the increased bacterial numbers in
the initial inoculum. Cytokines were also measured at the 1  106
dose, and production was correlated with bacterial burden, sup-
porting the hypothesis that bacterial load drives robust cytokine
production. Overall, the results show that an inflammatory re-
FIG 6 Murine cytokine/chemokine production in response to infection with high-dose ACT- and FHA-deficient bacteria. BALB/c mice were intranasally
inoculated with 50 l of PBS containing 5.5  105, 1  106, or 1  107 CFU of the cyaA fhaB strain (RB516) and 5.5  105 CFU from the fhaB strain (RBX9).
(A) Bacterial burden. Each point represents the number (log10) of CFU recovered from the right lungs of a single animal, and the data are from two independent
experiments. (B) Levels of TNF-, IL-1, IL-6, IL-17, KC, MIP-1, MIP-2, and MCP-1 were measured at 3 h, 48 h, and 72 h p.i. in lung homogenates of mice
inoculated with 5.5  105 CFU of the fhaB strain or the fhaB cyaA strain or 1  107 of the fhaB cyaA strain. Cytokines were assayed using Luminex
technology and standardized to a range of 3.2 to 22,000 pg/ml, depending on the analyte assayed. Dashed gray lines represent the upper limit of detection. The
cytokine profile of animals infected with the intermediate dose of 1  106 is not shown. Statistics are calculated as significant variation from the fhaB strain (*,
P 
 0.05; **, P 
 0.001; ***, P 
 0.0001).
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sponse can be generated in response to bacteria that lack ACT if
enough bacteria are present, and therefore ACT is not absolutely
required for the development of a proinflammatory response.
Effects of ACT- and FHA-deficient B. bronchiseptica on cy-
tokine production of unprimed bone marrow-derived macro-
phages. Our data suggest that both FHA and ACT influence the
inflammatory response to B. bronchiseptica infection, and we hy-
pothesize that they do so, at least in part, by controlling cytokine
and chemokine production in macrophages. To test this hypoth-
esis, we cultured bone marrow-derived macrophages with live
bacteria, added at an MOI of 10 into a 24-well plate containing 100
l of medium per well (so that both FHA-producing and FHA-
deficient bacteria would interact with the macrophages), for 2 h,
washed samples to remove any unattached bacteria, incubated
cultures for 24 h in medium containing gentamicin to kill remain-
ing extracellular bacteria, and then measured various cytokines by
ELISA. Enumeration of CFU at the end of the experiment indi-
cated that in all cases only approximately 0.1% of the bacteria had
been internalized and survived for 24 h (data not shown). Macro-
phages produced substantial amounts of IL-6 (8,919  2,241 pg/
ml), IL-10 (3,779  890 pg/ml), and IL-1 (954  285 pg/ml)
after culture with wild-type bacteria, indicating that an effective
proinflammatory response was generated. In contrast, wild-type
bacteria did not induce levels of TNF-, transforming growth fac-
tor 1 (TGF-1), or IL-12 that were above the detection limit of
the assay and induced only a modest amount of IL-23 (116  16
pg/ml). Cytokines induced by the mutant strains were compared
with those induced by wild-type B. bronchiseptica, levels of which
were set to 1 (Fig. 7). We observed a substantial amount of mac-
rophage cell death in response to infection by the fhaB strain.
Although we do not know the reason for the hypercytotoxicity of
this strain compared with wild-type bacteria, the cell death is likely
responsible for the large amount of TGF-1 present in the super-
natants of these cultures. No other cytokines were produced at
significantly different levels in response to the fhaB strain com-
pared with the response to wild-type bacteria. RBX1128 did not
cause hypercytotoxicity, and cytokine levels produced in response
to this strain were not statistically different from those produced
in response to wild-type bacteria. These data indicate that if FHA
causes changes in cytokine production in macrophages, those ef-
fects are not detectable in this assay. In contrast, significantly less
IL-1 and more TNF- and IL-12 were produced in response to
infection by the cyaA strain than in response to infection by
wild-type bacteria. These data suggest that ACT may function in
an anti-inflammatory capacity. Increased levels of IL-23 were pro-
duced in response to strains deficient in production of both ACT
and FHA, suggesting that ACT and FHA may function together to
suppress the production of this cytokine, which is involved in the
development of Th17 cells.
DISCUSSION
Studies on immunity to Bordetella have traditionally focused on
understanding the adaptive immune response to infection and
vaccination, and many, based primarily on observing IFN- pro-
duction by restimulated lymphocytes in vitro, led to the conclu-
sion that B. pertussis induces a Th1-type immune response (4, 30,
47, 54). These results have been perplexing, however, as it is well
established that Th1 responses control the development of cellular
immunity and clearance of intracellular pathogens (58), and Bor-
detella remains predominantly extracellular during infection. The
relatively recent discovery of Th17 cells and evidence that they
function as important mediators of inflammation and the control
of extracellular bacterial and fungal pathogens (18, 59, 73) have
prompted studies to explore the role of this pathway in controlling
Bordetella infection. Fedele et al. reported that human monocyte-
derived dendritic cells (MDDC) incubated with B. pertussis or
with lipooligosaccharide (LOS)/LPS from B. pertussis or human-
restricted Bordetella parapertussis in vitro produce IL-1, IL-6, and
FIG 7 Cytokine secretion in bone marrow-derived macrophages following infection with B. bronchiseptica. Bone marrow-derived macrophages were harvested
from 6-week-old C57BL/6J mice and allowed to culture for 7 days. Macrophages (106) were incubated for 2 h with 107 CFU of wild-type B. bronchiseptica or
mutant bacteria (MOI of 10). After incubation, cells were washed once with PBS, and growth medium was then supplemented with 30 g/ml gentamicin to kill
any remaining bacteria. Medium was harvested 24 h later, and cytokine production was assayed via ELISA. The lowest limit of detection was 10 pg/ml. Average
observed amounts of cytokines for RB50 (pg/ml) were as follows: IL-6, 8,919.56; IL-10, 3,779.35; TGF-1, 15.97; IL-1, 954.5; IL-23, 116.25; TNF-, 35.79; IL-12,
15. Results are fold changes relative to wild-type RB50 and are the average of six independent experiments. Asterisks indicate significant variation from the wild
type (*, P 
 0.05; **, P 
 0.001; ***, P 
 0.0001).
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IL-23 (cytokines involved in maturation of Th17 cells) and that
these MDDC could cause naïve lymphocytes to produce IL-17
(22, 23). Siciliano et al. similarly showed that macrophages pulsed
with B. bronchiseptica could induce splenocytes to secrete IL-17,
and they showed that lung tissue from mice inoculated with B.
bronchiseptica could produce IL-17 when restimulated in vitro
with B. bronchiseptica (61). Andreasen et al., using B. pertussis, also
provided evidence of a Th17 response to Bordetella infection (3).
Most recently, Dunne et al. showed that ACT could induce IL-1
production in LPS-activated macrophages, which could poten-
tially polarize a Th cell response toward the Th17 lineage, and they
also showed that IL-17/ mice were less able to control B. per-
tussis infection than wild-type mice (20). Consistent with these
studies, we showed in this study that wild-type B. bronchiseptica
induces a mild inflammatory response in the lungs of mice that is
characterized by the early induction of TNF- and the recruit-
ment of neutrophils and macrophages that stain positively for
IL-17.
Our previous investigations into the role of FHA in vivo
showed that intranasal inoculation of mice with our standard dose
(5  105 CFU) of FHA-deficient B. bronchiseptica results in a
bimodal response in which half of the animals become ill and are
moribund by day 3 to 4 p.i. and half remain healthy throughout
the course of the experiment (36, 40). We had hypothesized that
this bimodal phenotype was due to the production of a more
robust inflammatory response to infection by FHA-deficient bac-
teria that either clears the infection rapidly or causes tissue damage
that facilitates bacterial growth and consequently more inflamma-
tion, more immunopathology, and ultimately death of the mouse.
We reasoned that our standard dose was such that the inflamma-
tory response was precisely at a balance that could be tipped, on a
per animal basis, toward either bacterial clearance and recovery or
immunopathology-mediated death. The results of inoculating
mice with slightly higher and slightly lower doses support our
hypothesis; the bimodal response is dose dependent, and, signifi-
cantly, FHA-deficient bacteria induce a more robust inflamma-
tory response than wild-type bacteria even when a lower dose is
administered. These data support the conclusion that FHA func-
tions, either directly or indirectly, in an immunomodulatory ca-
pacity in vivo.
Our characterization of inflammatory cells in the lungs in re-
sponse to infection indicated that both wild-type and FHA-defi-
cient B. bronchiseptica caused the recruitment of large numbers of
neutrophils and monocyte-derived macrophages within 24 h
postinoculation. By 72 h p.i., the response to wild-type bacteria
shifted to one characterized by a large proportion of macrophages
and very few neutrophils. In contrast, a predominant neutrophil
response was sustained for at least 72 h in mice inoculated with
FHA-deficient bacteria, and a substantial proportion of those
neutrophils stained positively for IL-17. Production of IL-17 by
neutrophils has been documented under certain conditions (35,
42), including upon interaction with Bordetella virulence factors
(3). However, we cannot rule out the possibility that neutrophils
that stained positively for IL-17 in our experiments did so because
of IL-17 bound to surface receptors. Our data showed that mice
inoculated with FHA-deficient bacteria contained a greater per-
centage of IL-17-positive 	 T cells and a significantly greater
percentage of IL-17-positive CD4 T cells in their lungs, suggest-
ing the development of a Th17 response, which was not apparent
in mice infected with wild-type bacteria. Consistent with the sus-
tained neutrophil response, mice inoculated with FHA-deficient
bacteria had fewer numbers of CFU in their lungs at 72 h p.i. than
mice inoculated with wild-type bacteria, and we have now shown
in several experiments that most mice inoculated with FHA-defi-
cient B. bronchiseptica that remain healthy clear their infections
completely (from the lungs) by day 11 p.i. (36, 40; also the present
study). For mice inoculated with wild-type B. bronchiseptica, the
low proportion of neutrophils in the lungs at 72 h p.i. correlated
with higher numbers of bacteria at 72 h and a persistent lung
infection that lasts for at least 30 days (31, 32). These data suggest
that without FHA, B. bronchiseptica induces a Th17 response that
leads to rapid bacterial clearance. With FHA, B. bronchiseptica
causes a shift in the response to one that prevents the sustained
recruitment and activation of neutrophils, resulting in a persistent
infection. The fact that the host response and the outcome of
infection were similar for animals infected with the fhaB and
RBX1128 strains suggests that the role of FHA in vivo is not
solely to mediate attachment of the bacteria to host cells— unless
adherence to host cells in vivo does not correlate with adherence to
host cells in vitro.
Our data indicate that FHA is involved in suppressing the de-
velopment of an IL-17-mediated inflammatory response. We hy-
pothesize that one way in which it may do so is by altering signal-
ing pathways and, hence, cytokine and chemokine production in
macrophages, key regulators of T cell development. Although our
macrophage assay did not reveal a role for FHA in controlling
production of most of the cytokines that we measured, it did in-
dicate that both FHA and ACT are involved in suppressing pro-
duction of IL-23, one of the key cytokines involved in the devel-
opment of Th17 cells from naïve T cells (12, 34). Consistent with
our data demonstrating FHA-dependent suppression of inflam-
mation in vivo, McGuirk and Mills showed that purified FHA can
suppress IL-12 production in macrophages that have been primed
with E. coli LPS and/or IFN- in vitro (53), and Abramson et al.
showed that prolonged exposure to purified FHA could block
TNF--dependent NF-B activation in U-937 macrophages (1).
A major difference between our in vitro experiments and those of
McGuirk and Mills and of Abramson et al. is that we investigated
a role for FHA in the context of the whole bacterium while these
other investigators used purified FHA. We were surprised to find
that the fhaB strain induced hypercytotoxicity in macrophages
and are currently investigating the mechanism underlying this
phenotype. If FHA-mediated adherence functions to facilitate the
delivery of toxins to the host cell, we would expect the fhaB strain
to be hypocytotoxic, and therefore we hypothesize that the phe-
notype may reflect altered signaling in the macrophages due to
direct binding by FHA.
The robust inflammatory response that occurs in the absence
of FHA-mediated suppression indicates that one or more Borde-
tella factors function as potent activators of inflammation. Several
studies suggest that ACT functions in a proinflammatory way.
Mills and colleagues showed that purified ACT could induce
IL-1 production in LPS-stimulated dendritic cells in vitro and
that lymph node cells from immunized mice produce IL-17 in
response to restimulation with heat-inactivated ACT (20). Perkins
et al. showed that thioglycolate-elicited peritoneal macrophages
had higher transcript levels of COX-2 and IL-6 following treat-
ment with purified ACT (57), and Fedele et al. showed that
MDDC incubated with ACT-deficient B. pertussis were less able to
stimulate IL-17 production in cocultured T lymphocytes than
Henderson et al.
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MDDC that had been incubated with wild-type B. pertussis (23).
Siciliano et al. similarly showed that less IL-17 was produced when
splenocytes were incubated with macrophages that had been
pulsed with ACT-deficient B. bronchiseptica than when incubated
with macrophages pulsed with wild-type B. bronchiseptica (61).
Together, these data suggest that ACT functions to induce inflam-
mation, possibly by promoting the development of a Th17 re-
sponse. Apparently consistent with a proinflammatory role for
ACT, the lungs of mice inoculated with ACT-deficient B. bron-
chiseptica display less inflammation than those of mice infected
with wild-type bacteria (32) (Fig. 3). However, lack of a detectable
Th17 response in animals inoculated with ACT-deficient bacteria
could be due simply to the fact that these bacteria are cleared
rapidly, and therefore inflammation may already be resolving in
these mice at the times p.i. when IL-17 is detectable in the lungs of
mice infected with wild-type or FHA-deficient B. bronchiseptica.
We addressed this possibility by comparing the inflammatory re-
sponse to bacteria unable to produce FHA with that to bacteria
unable to produce both FHA and ACT administered at a critical
range of doses. When present in sufficiently high numbers, ACT-
deficient bacteria are able to induce a robust inflammatory re-
sponse, and both IL-1 and IL-17 are produced at increased levels.
ACT is therefore not absolutely required for the production of
IL-17 in animals infected with FHA-deficient bacteria. Further-
more, when bacterial numbers were similar, greater cytokine pro-
duction was detected in mice infected with fhaB cyaA double
mutant bacteria than those infected with the fhaB single mutant.
Consistent with this result, our in vitro experiments indicated that
macrophages infected with the fhaB cyaA double mutant se-
creted many cytokines at greater levels than macrophages infected
with the strain lacking only FHA. Although these data do not rule
out a possible proinflammatory role for ACT, they implicate an-
other factor as the driving force for the production of IL-17 in vivo.
There is evidence that Bordetella LOS/LPS may be involved in
the induction of a Th17 response. Fedele et al. have shown that
human dendritic cells secrete IL-1, IL-6, and IL-23 following
treatment with LOS/LPS from B. pertussis and human-restricted
B. parapertussis and that when these cells were cocultured with
purified T cells, IL-17 was detected in supernatants (22). Several
other studies have also demonstrated proinflammatory activities
of Bordetella LOS/LPS (24, 25, 44, 46, 62). The importance of
Toll-like receptor 4 (TLR4) signaling, which occurs in response to
LPS, in the host response to Bordetella has also been demonstrated
(6, 45, 70). We hypothesize, therefore, that Bordetella LOS/LPS
(and possibly other surface molecules) stimulates a proinflamma-
tory response via TLR signaling, resulting in the early recruitment
of neutrophils, macrophages, and dendritic cells to the site of in-
fection. However, we along with others have shown that FHA-
deficient B. pertussis strains are indistinguishable from wild-type
B. pertussis in mice, and no increase in lung inflammation in re-
sponse to the fhaB strain was observed (40, 65). A possible ex-
planation for the apparent discrepancy with results obtained from
studies with B. bronchiseptica is that fact that murine macrophages
are substantially less sensitive to B. pertussis LOS than human
macrophages (46). Thus, the roles of FHA and ACT may not be
apparent from studies using B. pertussis and mice because of in-
herent differences in the ability of mice and humans to respond to
the LOS of B. pertussis.
Together with our previous work, the data presented in this
study support roles for ACT both in surviving a neutrophil-medi-
ated response and in inactivation of macrophages, which would
lead to a decreased inflammatory response. While in vitro experi-
mentation provides substantial information about functional ca-
pabilities of ACT and its potential effects on host responses, in vivo
studies reveal that ACT is likely performing a myriad of functions
during the course of infection and may in fact be proinflammatory
under some circumstances and anti-inflammatory in others. Our
data suggest that both ACT and FHA may alter signaling in the
host such that cytokines that would lead to the development of a
Th17 response are suppressed. Since FHA and ACT have been
reported to bind CR3, an integrin involved in signal transduction,
it is possible that this interaction is necessary for immune modu-
lation. Studies are presently being conducted to determine if this
receptor is involved in controlling IL-17 production in the lungs.
ACT also suppresses cytokines that would push the T cell response
toward a Th1 profile. The result is a muted influx of inflammatory
cells that allows Bordetella to establish infection and persist in the
respiratory tract during the first week or so postinoculation.
To our knowledge, our study is the first to demonstrate sup-
pression of IL-17-mediated inflammation in vivo as a mechanism
to promote infection by a microbial pathogen. Moreover, we have
identified two bacterial factors involved, FHA and ACT. Although
Cheng et al. have proposed that Candida albicans downregulates
IL-17 production as a mechanism to promote commensal-like
colonization, their conclusions were drawn from in vitro studies
(14). While in vitro analyses using wild-type and mutant organ-
isms as well as purified proteins are essential for determining how
specific factors function mechanistically, they are necessarily re-
ductionist, and the results obtained must be interpreted within the
context of the analysis. Moreover, functions identified for specific
factors using in vitro analyses are likely to represent only a subset
of the functions actually performed by those factors in their native
context during the course of a natural infection. Reciprocally, de-
termining the roles of specific factors in pathogenesis from in vivo
studies is limited by the sheer complexity of the systems under
study, i.e., both the microbe and the host. While our current study
may have served to highlight our limited understanding of the
mechanisms underlying the Bordetella-host interaction, we be-
lieve that it represents a significant step toward closing the gap
between our knowledge of what specific factors can do in vitro and
what they actually do in vivo.
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